Olaparib
China [CN] Breast cancer and ovarian cancer are serious public health problems that seriously threaten women. However, in recent years, the growth rate of breast cancer incidence in China has been 1-2 percentage points higher than that in high-incidence countries. On the other hand, ovarian cancer remains the most severe challenge for gynecological oncologists. The reason is that there is no mature early diagnosis method for it. About 70% of patients are diagnosed at an advanced stage. Even if they achieve complete remission through effective treatment, 70% of patients will still relapse, and the 5-year survival rate has been hovering around 30-40%. Therefore, Chemicalbook attempts to establish a three-level prevention and control measure for ovarian cancer, just like other chronic diseases. A new therapeutic drug is urgently needed in the treatment of ovarian cancer, as platinum-based chemotherapy has a limited usage period until the side effects are intolerable. Olaparib and other PARP inhibitors under development are all oral preparations with better tolerance. Therefore, these drugs can be used for a longer period compared with traditional chemotherapy. Olaparib can prevent an enzyme involved in cell repair and is suitable for patients with certain genetic mutations.
Click enlarge Image